US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

• Egile Nagusiak: Richard J. Nowak (Egilea), Ali A. Habib (Egilea), Andrew J. Klink (Egilea), Srikanth Muppidi (Egilea), Anju Parthan (Egilea), S. Chloe Sader (Egilea), Alexandrina Balanean (Egilea), Ajeet Gajra (Egilea), James F. Howard (Egilea), ELEVATE Study Group (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background and Objective The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed to examine clinical-practice outcome data on eculizumab effect...